Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
Zonder
Jeffrey A
JA
Barlogie
Bart
B
Durie
Brian G M
BG
McCoy
Jason
J
Crowley
John
J
Hussein
Mohamad A
MA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use*; D003907:Dexamethasone / Q000009:adverse effects*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D012307:Risk Factors; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives*; D013923:Thromboembolism / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*; D013927:Thrombosis / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide; D001241:Aspirin